^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + AFM24 (EGFR inhibitor, CD16A agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AFFIMED ANNOUNCES POSITIVE DATA FOR AFM24 IN COMBINATION WITH THE PD-L1 CHECKPOINT INHIBITOR ATEZOLIZUMAB IN HEAVILY PRE-TREATED EGFR-WILDTYPE NON-SMALL CELL LUNG CANCER PATIENTS
Published date:
12/11/2023
Excerpt:
Affimed...announced interim safety and efficacy data on its innate cell engager (ICE®) AFM24 from the ongoing AFM24-102 combination study with atezolizumab, an anti-PD-L1 checkpoint inhibitor, in patients with advanced EGFR-expressing solid tumors. The data update as of December 6th, 2023, includes 15 patients from the EGFR-wildtype NSCLC cohort with a median of 2 prior lines of therapy. Importantly, all patients were pretreated with and ultimately progressed while on PD-[L]1 targeting therapy....The combination of AFM24 with atezolizumab showed encouraging signals of clinical activity, including 1 unconfirmed CR, 3 PRs (1 confirmed, 2 unconfirmed) and 7 patients exhibiting SD.
Trial ID:
